U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Aprea Therapeutics

Market Cap: US$8.7m

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.

Prothena

Market Cap: US$441.9m

A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.

Cumberland Pharmaceuticals

Market Cap: US$54.8m

A specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally.

Alkermes

Market Cap: US$4.8b

A biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.

BridgeBio Oncology Therapeutics

Market Cap: US$871.4m

A clinical-stage biopharmaceutical company, engages in the development of small molecule inhibitor for cancer patients.

Whitehawk Therapeutics

Market Cap: US$85.3m

An oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.

Alumis

Market Cap: US$478.7m

A clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.

Shattuck Labs

Market Cap: US$72.3m

A biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases.

Ocular Therapeutix

Market Cap: US$2.2b

A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.

Kalaris Therapeutics

Market Cap: US$87.2m

A clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases.

Natera

Market Cap: US$22.9b

A diagnostics company, provides molecular testing services worldwide.

vTv Therapeutics

Market Cap: US$132.8m

A clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases.

Edgewise Therapeutics

Market Cap: US$1.5b

A biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.

Avadel Pharmaceuticals

Market Cap: US$1.5b

Operates as a biopharmaceutical company in the United States.

Lexicon Pharmaceuticals

Market Cap: US$388.8m

A biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.

Neurogene

Market Cap: US$279.9m

A clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.

Avidity Biosciences

Market Cap: US$6.2b

A biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs).

Ginkgo Bioworks Holdings

Market Cap: US$647.4m

Develops a platform for cell programming in the United States.

Phio Pharmaceuticals

Market Cap: US$11.8m

A a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States.

ORIC Pharmaceuticals

Market Cap: US$1.0b

A clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States.

Immunovant

Market Cap: US$2.8b

A clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.

Dyne Therapeutics

Market Cap: US$1.9b

A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.

Aurinia Pharmaceuticals

Market Cap: US$1.6b

A biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs.

Arcturus Therapeutics Holdings

Market Cap: US$484.7m

Engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases.

Tyra Biosciences

Market Cap: US$674.2m

A clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.

Arbutus Biopharma

Market Cap: US$805.1m

A clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.

Tonix Pharmaceuticals Holding

Market Cap: US$230.6m

A biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease.

AbCellera Biologics

Market Cap: US$1.2b

Engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

Moderna

Market Cap: US$9.4b

A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.

SNDL

Market Cap: US$627.9m

Engages in the production, distribution, and sale of cannabis products for the adult-use market in Canada.

Agios Pharmaceuticals

Market Cap: US$2.1b

A biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.

Generation Bio

Market Cap: US$40.3m

A biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells.

10x Genomics

Market Cap: US$1.7b

A life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific.

OpGen

Market Cap: US$1.0k

A precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally.

Capricor Therapeutics

Market Cap: US$271.6m

A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

SAB Biotherapeutics

Market Cap: US$23.5m

A clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders.